circle

INVESTORS & MEDIA

PRESS RELEASES

There are currently no events to display.

Keyword Search

Press Release Archive 1998-2005
Date Title  
November 7, 2022
Cytokinetics Presents New Data at the American Heart Association Scientific Sessions 2022
link
November 3, 2022
Cytokinetics Reports Third Quarter 2022 Financial Results
link
November 1, 2022
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
link
October 31, 2022
Cytokinetics Announces Three Upcoming Presentations at the American Heart Association Scientific Sessions 2022
link
October 20, 2022
Cytokinetics to Announce Third Quarter Results on November 3, 2022
link
October 10, 2022
Cytokinetics Announces Continuation of COURAGE-ALS Following First Interim Analysis
link
October 3, 2022
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
link
October 2, 2022
Cytokinetics Presents New Data From REDWOOD-HCM OLE in Late Breaking Clinical Trial Session at the HFSA Annual Scientific Meeting
link
September 30, 2022
Cytokinetics Presents New Data From REDWOOD-HCM OLE in Late Breaking Clinical Trial Session at the HCM Society Scientific Sessions
link
September 28, 2022
Cytokinetics Announces Call for Proposals for Its Fifth Annual Communications Grant Program
link
September 26, 2022
Cytokinetics Announces Upcoming Presentations at the 2022 Inaugural HCM Society Scientific Sessions and the HFSA Annual Scientific Meeting
link
September 6, 2022
Cytokinetics to Participate in Upcoming Investor Conferences
link
September 1, 2022
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
link
August 4, 2022
Cytokinetics Reports Second Quarter 2022 Financial Results
link
August 4, 2022
Cytokinetics and The ALS Association Announce Release of Updated PRO-ACT Database Including Data From Cytokinetics’ Completed ALS Clinical Trials
link
August 1, 2022
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
link
July 21, 2022
Cytokinetics to Announce Second Quarter Results on August 4, 2022
link
July 5, 2022
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
link
July 1, 2022
Cytokinetics Announces Pricing of $450 Million Convertible Senior Notes Offering
link
June 29, 2022
Cytokinetics Announces Proposed Convertible Senior Notes Offering
link
June 24, 2022
Cytokinetics Announces Date for FDA Advisory Committee Meeting to Review New Drug Application for Omecamtiv Mecarbil
link
June 17, 2022
Cytokinetics Provides Regulatory Update for Omecamtiv Mecarbil
link
June 16, 2022
Cytokinetics Announces Start of Open-Label Extension Study for Patients Completing COURAGE-ALS
link
June 13, 2022
Cytokinetics Announces Additional Data From REDWOOD-HCM Presented at the American Society of Echocardiography 33rd Annual Scientific Sessions
link
June 3, 2022
Cytokinetics Announces Additional Results From REDWOOD-HCM to Be Presented at the American Society of Echocardiography 33rd Annual Scientific Sessions
link
June 2, 2022
Cytokinetics to Participate in Upcoming Investor Conferences
link
June 1, 2022
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
link
May 23, 2022
Cytokinetics Announces Data From REDWOOD-HCM OLE and GALACTIC-HF Presented as Late Breaking Science Presentations at the European Society of Cardiology Heart Failure 2022 Congress
link
May 18, 2022
Cytokinetics and the ALS Association Renew Partnership to Advance the Fight Against ALS
link
May 17, 2022
Cytokinetics to Participate in the 2022 H.C. Wainwright Global Life Sciences Conference
link
May 17, 2022
Cytokinetics Provides Regulatory Update Related to New Drug Application for Omecamtiv Mecarbil
link
May 16, 2022
Cytokinetics Announces Three Upcoming Presentations at the European Society of Cardiology Heart Failure 2022 Congress
link
May 4, 2022
Cytokinetics Reports First Quarter 2022 Financial Results
link
May 3, 2022
Cytokinetics to Hold Annual Meeting of Stockholders
link
April 20, 2022
Cytokinetics to Announce First Quarter Results on May 4, 2022
link
April 8, 2022
Cytokinetics Announces Changes to Board of Directors
link
April 6, 2022
Cytokinetics to Participate in the 21st Annual Needham Virtual Healthcare Conference
link
April 3, 2022
Cytokinetics Announces Results From METEORIC-HF and Additional Data From GALACTIC-HF Presented at the American College of Cardiology 71st Annual Scientific Session
link
April 2, 2022
Cytokinetics Announces Results From Cohort 3 of REDWOOD-HCM Presented at American College of Cardiology 71st Annual Scientific Session
link
April 1, 2022
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
link
March 24, 2022
Cytokinetics Announces Four Upcoming Presentations at the American College of Cardiology 71st Annual Scientific Session & Expo
link
March 8, 2022
Cytokinetics to Participate in Upcoming Investor Conferences
link
March 2, 2022
Cytokinetics Announces Cohort 4 of REDWOOD-HCM Is Open to Enrollment
link
March 1, 2022
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
link
February 28, 2022
Cytokinetics Joins Global Initiative to Recognize International Rare Disease Day
link
February 24, 2022
Cytokinetics Reports Fourth Quarter 2021 Financial Results
link
February 23, 2022
Cytokinetics Announces Start of SEQUOIA-HCM, a Phase 3 Clinical Trial of Aficamten in Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy
link
February 16, 2022
Cytokinetics and the American Heart Association Bay Area Announce a Three-Year Collaboration to Advance Education and Awareness of Heart Disease
link
February 15, 2022
Cytokinetics Announces Topline Results From METEORIC-HF
link
February 10, 2022
Cytokinetics to Announce Fourth Quarter Results on February 24, 2022
link
February 4, 2022
Cytokinetics Announces FDA Acceptance of New Drug Application for Omecamtiv Mecarbil for the Treatment of Heart Failure With Reduced Ejection Fraction
link
February 1, 2022
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
link
February 1, 2022
Cytokinetics Announces Positive Topline Results from Cohort 3 of REDWOOD-HCM
link
January 24, 2022
Cytokinetics Announces Recipients of Fourth Annual Communications Fellowship Grants
link
January 10, 2022
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
link
January 7, 2022
Cytokinetics and Royalty Pharma Announce Funding Agreements Totaling up to $450 Million
link
January 3, 2022
Cytokinetics to Participate in the 40th Annual J.P. Morgan Healthcare Conference
link